Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900795 · ClinicalTrials.gov registry record · Phase 2
An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction
A Phase 2 study, sponsored by Purdue Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT01900795 is a Phase 2 study that was terminated before completion, run by Purdue Pharma. The registered enrollment target is 114 participants.
The verdict
NCT01900795, a Phase 2 study, was terminated before completion, sponsored by Purdue Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the analgesic properties of an oral dose of V117957 4.5 mg aqueous suspension in the third molar extraction model
Interventions
- DRUG Placebo
- DRUG Ibuprofen
- DRUG V117957
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900795
The ClinicalTrials.gov registry entry for NCT01900795 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01900795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900795 about?
NCT01900795 is a clinical study titled "An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction". The primary objective of this study is to assess the analgesic properties of an oral dose of V117957 4.5 mg aqueous suspension in the third molar extraction model
What is the current status of trial NCT01900795?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2013-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01900795?
The interventions under investigation include: Placebo (DRUG), Ibuprofen (DRUG), V117957 (DRUG).
Who is sponsoring clinical trial NCT01900795?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.